Follicum has received information that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance of the US patent application.
The patent application covers the company’s peptides and their use for treatment of diabetes and diabetes-associated complications.
The application is directed to new peptides from the company’s two peptide classes, and their use in the treatment of diabetes and its complications. Follicum has now received Notice of Allowance for this application. In short, a Notice of Allowance means that the patent office in question (the USPTO), intends to grant a patent application following the implementation of certain administrative measures by both parties. When the patent is finally granted, it can be kept in force until 2038.
“This Notice of Allowance of the patent demonstrates the uniqueness of our diabetes project and it lays the ground for commercialization opportunities in the US, one of the largest markets for diabetes medicines. The announcement from the US Patent Office is thus creating significant value for Follicum,” says CEO Jan Alenfall.
Photo of Jan Alenfall